A post-hoc analysis on 696 patients with T2D from three randomized, double-blind, placebo-controlled studies showed that adding colesevelam (3.75 g/d) to metformin compared to placebo significantly decreased HbA1c (−0.5%) and fasting plasma glucose (−15.7 mg/dL), and reduced levels of total cholesterol (−5.8%), LDL-C (−16.5%), apoB (−7.6%) and non-HDL-C (−8.2%), but triglyceride levels increased (+12.8%) [84]. The gene discussed is APOB; the disease is type 2 diabetes mellitus.